Comparative Pharmacology
Head-to-head clinical analysis: BLEPH 10 versus BLEPH 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLEPH 10 versus BLEPH 30.
BLEPH-10 vs BLEPH-30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking the conversion of p-aminobenzoic acid (PABA) to dihydrofolate, thereby inhibiting bacterial folic acid synthesis and exerting bacteriostatic activity.
BLEPH-30 is a topical formulation containing 30% sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, interfering with folic acid synthesis and exerting bacteriostatic activity against susceptible organisms.
Instill 1-2 drops into the conjunctival sac every 3-4 hours, initially up to every 2 hours for severe infections.
One drop to the affected eye(s) every 12 hours. Not to exceed 2 drops per eye per day.
None Documented
None Documented
Terminal elimination half-life is 60-90 minutes in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 2.5 hours in adults with normal renal function; clinically, dosing intervals may need adjustment in renal impairment.
Renal excretion of unchanged drug accounts for approximately 50-70% of the dose; biliary/fecal excretion is minimal (<10%).
Primarily renal excretion of unchanged drug, accounting for approximately 90% of elimination; minor biliary/fecal route (<10%).
Category C
Category C
Ophthalmic Antibiotic
Ophthalmic Antibiotic